Whether you’re newly diagnosed or more experienced in managing relapsing multiple sclerosis (RMS), living with the disease can be unpredictable. Starting or staying with a treatment is an important decision, and that’s why it is crucial to research different treatment options. When you and your healthcare provider are discussing what you want out of your treatment, you may want to keep these 3 important goals in mind:
All RMS treatments have an effect on the immune system, your body’s natural defense system against harmful substances such as viruses, fungi, bacteria, toxins, and foreign particles. Although treatment may help reduce the frequency of relapses, it could also make you more vulnerable to many of the illnesses or medical challenges from which your immune system usually protects you. That’s why considering both safety and efficacy is important. Work with your healthcare provider to find an RMS treatment option that is right for you.
*People with insurance or co-insurance may be eligible.
†Attention Patients: Federal and state healthcare program beneficiaries are not eligible for the MS LifeLines® $0 co-pay program. If you participate in a federal or state healthcare program, including Medicare, Medicaid, TRICARE, the Department of Veterans Affairs, the Department of Defense, or any other similar federal or state healthcare program, including any state medical pharmaceutical assistance program, you are not eligible to utilize the MS LifeLines® $0 co-pay program.
IMPORTANT SAFETY INFORMATION AND INDICATION
Important Safety Information
Do not take Rebif if you are allergic to interferon beta, human albumin, or any of the ingredients in Rebif.
Rebif can cause serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while taking Rebif.
Before you take Rebif, tell your healthcare provider if you have or have had any of the following conditions:
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of Rebif include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Rebif. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Indication
Rebif® (interferon beta-1a) is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if Rebif is safe and effective in children.
Please see Rebif® Prescribing Information and Medication Guide.
IMPORTANT SAFETY INFORMATION AND INDICATION
Important Safety Information
Do not take Rebif if you are allergic to interferon beta, human albumin, or any of the ingredients in Rebif.
Rebif can cause serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while taking Rebif.
Before you take Rebif, tell your healthcare provider if you have or have had any of the following conditions:
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of Rebif include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Rebif. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Indication
Rebif® (interferon beta-1a) is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if Rebif is safe and effective in children.
Please see Rebif® Prescribing Information and Medication Guide.
US-REB-00449
Last update 08/2023
This website is intended only for residents of the United States.
Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. Rebif,
MS LifeLines, Rebiject II, Rebidose, and the Rebif logo are registered trademarks of Merck KGaA, Darmstadt, Germany, or its affiliates.
©2023 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono Inc.
US-REB-00449
Last update 08/2023
